650P - Efficacy and tolerability of first-line chemotherapy in elderly patients (age ≥70 years) with metastatic gastric cancer: a multicenter study of the...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gastric Cancer
Presenter Mehmet Aldemir
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors M.N. Aldemir1, M. Turkeli2, B. Hacioglu3, A. Sakin4, E. Yaman5, E. Coban6, D. Koca7, M. Karaca8, M. Simsek2, A. Bahceci9, E. Sen10, T. Eren11, B.Ö. Aliustaoglu12, T. Sakalar13, N.O. Kalkan14, G. Aktas15, M. Bilici2, S. Turhal16, M. Benekli8, S.B. Tekin2
  • 1Medical Oncology, Ataturk University Medical Faculty, 25242 - Erzurum/TR
  • 2Medical Oncology, Ataturk University Medical Faculty, Erzurum/TR
  • 3Medical Oncology, Trakya University Rektörlüğü, Edirne/TR
  • 4Medical Oncology, S.B. Okmeydani Education And Research Hospital, Istanbul/TR
  • 5Medical Oncology, Mersin University School of Medicine, Mersin/TR
  • 6Medical Oncology, Bezmialem Vakif University Hospital, Istanbul/TR
  • 7Medical Oncology, Medical Park Hospital, Kocaeli/TR
  • 8Medical Oncology, GUTF (Gazi Üniversitesi Tip Fakültesi)-Gazi University Faculty of Medicine, Ankara/TR
  • 9Medical Oncology, Cumhuriyet University Hospital, Sivas/TR
  • 10Medical Oncology, Selcuk University Meram Medical Faculty, Konya/TR
  • 11Medical Oncology, Diskapi Yıldırım Beyazıt Teaching and Research Hospital, Ankara/TR
  • 12Medical Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul/TR
  • 13Medical Oncology, Erciyes University Medical Faculty M.Kemal Dedeman, Oncology Hospital, Kayseri/TR
  • 14Medical Oncology, Yuzuncu Yil University Medical Faculty, Van/TR
  • 15Medical Oncology, Gaziantep University Onkoloji Hastanesi, Gaziantep/TR
  • 16Medical Oncology, Anadolu Medical Center, Kocaeli/TR

Abstract

Background

Gastric cancer that is generally diagnosed in advanced stages is the second leading cause of cancer-related death worldwide. Although chemotherapy has benefit on quality of life and overall survival (OS) in metastatic gastric cancer (MGC), OS usually remains less than a year. Here, the efficacy and tolerability of first-line chemotherapy in MGC patients aged 70 years and older was investigated

Methods

As a multicenter study of ASMO, 305 patients followed in 17 centers between 2005 and 2015 were included. Patients who were 70 years and older at the time of MGC diagnosis and who had received at least two cycles of chemotherapy in the first-line setting were evaluated retrospectively.

Results

The clinical and demographical features of the patients were presented in Table 1. Median age was 73 (min-max 70-90). Median follow-up time was determined as 8 months (min-max 1-78), median PFS as 6 months (95%CI: 5.2-6.7) and median OS as 10 months (95%CI: 8.4-11.6). Partial response was achieved in 26.2% and stable disease in 16.7% of the patients. The most common chemotherapy related grade 3-4 hematologic toxicity was neutropenia (22%). Poor ECOG performance status, history of surgical treatment and less number of metastatic organs had statistically significant benefit on PFS and OS (p 

Conclusions

We observed that first-line chemotherapy was effective and tolerable in elderly patients. The chemotherapy regimen (multiple or single) and the dose reduction at the beginning did not affect treatment response. It is reasonable to choose the minimum toxic and maximum tolerable chemotherapy regimen. It will be more relevant to use physiological age evaluations like ECOG performance status than biological age in treatment decision.

Clinical trial identification

Legal entity responsible for the study

Anatolian Society of Medical Oncology (ASMO)

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.